Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al

Ann Rheum Dis. 2022 Aug;81(8):e135. doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.

Authors

Kristin M D'Silva¹, Naomi Serling-Boyd¹, Rachel Wallwork¹, Tiffany Y-T Hsu², Jeffrey A Sparks², Zachary Scott Wallace³

Affiliations

¹ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA zswallace@partners.org.

PMID: 32660976
DOI: 10.1136/annrheumdis-2020-218431

No abstract available

Keywords: antirheumatic agents; arthritis, rheumatoid; epidemiology; health services research.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Letter
Comment

MeSH terms

Antirheumatic Agents* / therapeutic use
COVID-19*
Humans
Rheumatic Diseases* / complications
Rheumatic Diseases* / drug therapy

Substances

Antirheumatic Agents

Grants and funding